GLPG1205 is novel, specific, orally bioactive and negative allosteric GPR84 antagonist with a favorable PK/PD profiles. GLPG1205 has anti-inflammatory activity and is used for the treatment of pulmonary fibrosis. GLPG1205 reduced disease activity index score and neutrophil infiltration in a mouse dextran sodium sulfate-induced chronic inflammatory bowel disease model, with efficacy similar to positive-control compound sulfasalazine. The drug discovery steps leading to GLPG1205 identification, currently under phase II clinical investigation, are described herein.

纯度：≥98%

CAS：1445847-37-9